Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684-01A Umbrella Substudy in mCRPC (Japan)
jRCT2031240224Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities (DLTs), Adverse events (AEs) and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031240224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240224.